WO2005014032A3 - Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite - Google Patents

Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite Download PDF

Info

Publication number
WO2005014032A3
WO2005014032A3 PCT/DK2004/000529 DK2004000529W WO2005014032A3 WO 2005014032 A3 WO2005014032 A3 WO 2005014032A3 DK 2004000529 W DK2004000529 W DK 2004000529W WO 2005014032 A3 WO2005014032 A3 WO 2005014032A3
Authority
WO
WIPO (PCT)
Prior art keywords
ghrelin
medicament
individual
relates
present
Prior art date
Application number
PCT/DK2004/000529
Other languages
French (fr)
Other versions
WO2005014032A2 (en
WO2005014032B1 (en
Inventor
Birgitte Holst Lange
Christian Hansen
Henrik Nilsson
Original Assignee
Gastrotech Pharma As
Birgitte Holst Lange
Christian Hansen
Henrik Nilsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastrotech Pharma As, Birgitte Holst Lange, Christian Hansen, Henrik Nilsson filed Critical Gastrotech Pharma As
Priority to JP2006522237A priority Critical patent/JP2007523048A/en
Priority to US10/567,406 priority patent/US20070037751A1/en
Priority to EP04739026A priority patent/EP1660117A2/en
Publication of WO2005014032A2 publication Critical patent/WO2005014032A2/en
Publication of WO2005014032A3 publication Critical patent/WO2005014032A3/en
Publication of WO2005014032B1 publication Critical patent/WO2005014032B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.
PCT/DK2004/000529 2003-08-06 2004-08-06 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite WO2005014032A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006522237A JP2007523048A (en) 2003-08-06 2004-08-06 Use of secretagogues
US10/567,406 US20070037751A1 (en) 2003-08-06 2004-08-06 Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP04739026A EP1660117A2 (en) 2003-08-06 2004-08-06 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
DKPA200301139 2003-08-06
DKPA200301139 2003-08-06
DKPA200301140 2003-08-06
DKPA200301140 2003-08-06
US49481503P 2003-08-14 2003-08-14
US49481603P 2003-08-14 2003-08-14
US60/494,816 2003-08-14
US60/494,815 2003-08-14
DKPA200301283 2003-09-05
DKPA200301283 2003-09-05
DKPA200301570 2003-10-24
DKPA200301570 2003-10-24
DKPA200301569 2003-10-24
DKPA200301569 2003-10-24
DKPA200400570 2004-04-07
DKPA200400570 2004-04-07

Publications (3)

Publication Number Publication Date
WO2005014032A2 WO2005014032A2 (en) 2005-02-17
WO2005014032A3 true WO2005014032A3 (en) 2005-03-17
WO2005014032B1 WO2005014032B1 (en) 2005-04-28

Family

ID=34139992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000529 WO2005014032A2 (en) 2003-08-06 2004-08-06 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite

Country Status (3)

Country Link
EP (1) EP1660117A2 (en)
JP (1) JP2007523048A (en)
WO (1) WO2005014032A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
US20080171700A1 (en) * 2004-04-07 2008-07-17 Gastrotech Pharma A/S Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
KR20070050871A (en) * 2004-05-11 2007-05-16 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 Methods of inhibiting proinflammatory cytokine expression using ghrelin
EP1781311A4 (en) * 2004-08-18 2010-02-17 Elixir Pharmaceuticals Inc Growth-hormone secretagogues
WO2006045314A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
CA2645844C (en) * 2006-03-13 2016-04-26 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
US7763707B2 (en) * 2006-03-13 2010-07-27 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite-stimulation
ES2599168T3 (en) * 2010-01-15 2017-01-31 University Of Miyazaki Ghrelin to promote the recovery of an animal under medical treatment
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
AP2017009772A0 (en) 2014-09-04 2017-02-28 Helsinn Healthcare Sa Medical treatments based on anamorelin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO2001056592A1 (en) * 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
EP1186293A2 (en) * 2000-08-30 2002-03-13 Pfizer Products Inc. Intermittent administration of a growth hormone secretagogue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04177224A (en) * 1990-11-09 1992-06-24 Sharp Corp Liquid crystal display device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO2001056592A1 (en) * 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
EP1186293A2 (en) * 2000-08-30 2002-03-13 Pfizer Products Inc. Intermittent administration of a growth hormone secretagogue

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAGAYA NORITOSHI ET AL: "Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure.", CURRENT OPINION IN PHARMACOLOGY, vol. 3, no. 2, April 2003 (2003-04-01), pages 146 - 151, XP002311021, ISSN: 1471-4892 *
VAN DEN BERGHE GREET: "Growth hormone secretagogues in critical illness", HORMONE RESEARCH (BASEL), vol. 51, no. Suppl. 3, November 1999 (1999-11-01), & THE TENTH HGH SYMPOSIUM; SEVILLE, SPAIN; APRIL 23-24, 1999, pages 21 - 28, XP009041731, ISSN: 0301-0163 *
WREN A M ET AL: "GHRELIN ENHANCES APPETITE AND INCREASES FOOD INTAKE IN HUMANS", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 86, no. 12, December 2001 (2001-12-01), pages 5992 - 5995, XP001156529, ISSN: 0021-972X *

Also Published As

Publication number Publication date
EP1660117A2 (en) 2006-05-31
JP2007523048A (en) 2007-08-16
WO2005014032A2 (en) 2005-02-17
WO2005014032B1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
EP2460522A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP2561874A3 (en) Pharmaceutical compositions for treating cancer
ZA200104396B (en) Compositions and methods for stimulating gastrointestinal motility.
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
IL171683A (en) Immunosuppressant compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
MX2007015480A (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption.
ZA200802811B (en) Therapy for the treatment of disease
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
WO2004009015A3 (en) Combination therapy for the treatment of obesity
HUP0401174A3 (en) Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MXPA04005156A (en) Adenosine a2a.
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
WO2005014032A3 (en) Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
SE9901573D0 (en) New compounds
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
CA2385755A1 (en) Prevention of colorectal cancer
WO2007139433A8 (en) Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application
WO2005097174A3 (en) Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
MXPA03010919A (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029235.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20050314

WWE Wipo information: entry into national phase

Ref document number: 2006522237

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004739026

Country of ref document: EP

Ref document number: 784/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004739026

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007037751

Country of ref document: US

Ref document number: 10567406

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10567406

Country of ref document: US